

# The complete genome, comparative and functional analysis of *Stenotrophomonas maltophilia* reveals an organism heavily shielded by drug resistance determinants

Lisa C Crossman<sup>\*</sup>, Virginia C Gould<sup>†</sup>, J Maxwell Dow<sup>‡</sup>, Georgios S Vernikos<sup>\*</sup>, Aki Okazaki<sup>†</sup>, Mohammed Sebahia<sup>\*</sup>, David Saunders<sup>\*</sup>, Claire Arrowsmith<sup>\*</sup>, Tim Carver<sup>\*</sup>, Nicholas Peters<sup>\*</sup>, Ellen Adlem<sup>\*</sup>, Arnaud Kerhornou<sup>\*</sup>, Angela Lord<sup>\*</sup>, Lee Murphy<sup>\*</sup>, Katharine Seeger<sup>\*</sup>, Robert Squares<sup>\*</sup>, Simon Rutter<sup>\*</sup>, Michael A Quail<sup>\*</sup>, Mari-Adele Rajandream<sup>\*</sup>, David Harris<sup>\*</sup>, Carol Churcher<sup>\*</sup>, Stephen D Bentley<sup>\*</sup>, Julian Parkhill<sup>\*</sup>, Nicholas R Thomson<sup>\*</sup> and Matthew B Avison<sup>†</sup>

Addresses: <sup>\*</sup>Pathogen Sequencing Unit, The Wellcome Trust Sanger Institute, Hinxton, Cambridge, CB10 1SA, UK. <sup>†</sup>Department of Cellular and Molecular Medicine, University of Bristol, School of Medical Sciences, University Walk, Bristol, BS8 1TD, UK. <sup>‡</sup>Biomerit Research Centre, Department of Microbiology, Biosciences Institute, National University of Ireland, Cork, Ireland.

Correspondence: Julian Parkhill. Email: parkhill@sanger.ac.uk. Matthew B Avison. Email: matthewb.avison@bristol.ac.uk

Published: 17 April 2008

Genome **Biology** 2008, **9**:R74 (doi:10.1186/gb-2008-9-4-r74)

The electronic version of this article is the complete one and can be found online at <http://genomebiology.com/2008/9/4/R74>

Received: 14 January 2008

Revised: 13 March 2008

Accepted: 17 April 2008

© 2008 Crossman *et al.*; licensee BioMed Central Ltd.

This is an open access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

## Abstract

**Background:** *Stenotrophomonas maltophilia* is a nosocomial opportunistic pathogen of the Xanthomonadaceae. The organism has been isolated from both clinical and soil environments in addition to the sputum of cystic fibrosis patients and the immunocompromised. Whilst relatively distant phylogenetically, the closest sequenced relatives of *S. maltophilia* are the plant pathogenic xanthomonads.

**Results:** The genome of the bacteremia-associated isolate *S. maltophilia* K279a is 4,851,126 bp and of high G+C content. The sequence reveals an organism with a remarkable capacity for drug and heavy metal resistance. In addition to a number of genes conferring resistance to antimicrobial drugs of different classes via alternative mechanisms, nine resistance-nodulation-division (RND)-type putative antimicrobial efflux systems are present. Functional genomic analysis confirms a role in drug resistance for several of the novel RND efflux pumps. *S. maltophilia* possesses potentially mobile regions of DNA and encodes a number of pili and fimbriae likely to be involved in adhesion and biofilm formation that may also contribute to increased antimicrobial drug resistance.

**Conclusion:** The panoply of antimicrobial drug resistance genes and mobile genetic elements found suggests that the organism can act as a reservoir of antimicrobial drug resistance determinants in a clinical environment, which is an issue of considerable concern.

## Background

The rise of antimicrobial drug resistance in bacteria is one of the biggest threats to healthcare provision in the developed world. Few new antimicrobial drugs are undergoing clinical trials, and almost none are effective against Gram-negative multi-drug resistant (MDR) pathogens [1]. A return to the pre-antibiotic era is a possibility, and for some infections is the current reality [2].

Antimicrobial resistance in historically common pathogens is usually either acquired on a mobile genetic element or results from a mutation [3]. However, some opportunistic pathogens are intrinsically resistant to the actions of a number of antimicrobial classes. These tend to be of environmental origin, and their intrinsic drug resistance determinants either provide resistance to antibiotics produced by competitors, or represent broad-spectrum methods for removing toxic compounds or waste products that, by chance, protect against antimicrobials [3,4]. It is known that established opportunistic infections are very difficult to treat due to the MDR nature of the causative bacteria [5].

The most common intrinsically MDR opportunistic pathogens are the non-fermenting Gram-negative bacilli typified by *Pseudomonas aeruginosa*. In this case, intrinsic resistance is due to a battery of efflux pumps, specific antibiotic hydrolyzing enzymes, and intrinsically low outer membrane permeability. When intrinsically MDR bacteria then acquire resistance to those few drugs that can kill them, the result is an isolate resistant to all clinically available antimicrobials. This pan-resistant phenotype is observed in *P. aeruginosa* isolates with increasing frequency [6].

*S. maltophilia* is the third most common nosocomial non-fermenting Gram-negative bacilli [7]. A recent study of intensive care patients in the USA found that 4.3% of almost 75,000 Gram-negative infections studied were caused by *S. maltophilia* [8]. Isolates are intrinsically resistant to  $\beta$ -lactams, aminoglycosides, macrolides, and many older quinolones [7].

*S. maltophilia* is found in soil and water, and routinely resides in showerheads and other moist places where it grows as biofilm. It is a truly opportunistic pathogen, and patient to patient spread has not been reported, though small outbreaks have been seen due to contaminated water sources [9]. Consistent with this, we find that isolates are generally genotypically and phenotypically diverse [10-12]. However, there is phylogenetic clustering, with about half of clinical isolates being very similar to each other, even across a wide geographical range. Members of this group, termed phylogenetic group A, may be better at causing infections than other *S. maltophilia* isolates [13]. The two most common diseases caused by *S. maltophilia* are bacteremia and pneumonia with infection being via an indwelling catheter or ventilator, respectively [9]. Respiratory tract colonization is seen in about a third of all cystic fibrosis (CF) patients; nevertheless, there is

controversy as to whether this leads to a poorer clinical outcome or morbidity [14,15].

Bioinformatic and functional genomic analyses on the complete genome sequence emphasize factors with proven or potential contribution to antibiotic resistance, persistence and virulence. The findings reveal the remarkable capacity of *S. maltophilia* for multidrug resistance and environmental adaptability that underpins its importance as an emerging opportunistic nosocomial pathogen.

## Results and discussion

### Total genome overview


The sequenced isolate is from a typical presentation: an elderly male patient undergoing chemotherapy at the Bristol Oncology Unit, Bristol, UK in 1998 developed a bloodstream infection that did not respond to therapy with piperacillin/tazobactam, ceftazidime or imipenem. *S. maltophilia* K279a was cultured from a blood sample taken shortly before death [16]. K279a falls into phylogenetic group A, and has typical antimicrobial resistance properties [13,17,18]. Accordingly, it was thought suitable as a representative genome sequence strain.

The genome consists of a single circular chromosome; no plasmids were detected (Figure 1). The total size is 4,851,126 bp with a G+C content of 66.7% G+C. Four copies of the rRNA operon and 74 tRNAs are present. These data have been submitted to EMBL under accession number AM743169.

### Drug resistance

In Gram-negative nosocomial pathogens, MDR is usually mediated by the over-production of resistance-nodulation-division (RND) type efflux pumps. These pumps tend to have broad substrate profiles, including organic solvents, disinfectants and antimicrobial drugs from a number of different classes. Cytoplasmic efflux is driven by dissipation of the proton-motive force across the inner membrane. Two additional components are needed to remove substrates from the cell, forming a tripartite efflux pump complex that spans the envelope. A particular periplasm-spanning membrane-fusion protein (MFP) is usually specific to each RND efflux protein, and it is common to find the pair encoded as part of an operon. A third component, the outer membrane protein (OMP), can be encoded in the same operon, but there tend to be fewer different OMPs than RND/MFP pairs in a cell, meaning that the OMPs are often promiscuous [19].

The K279a sequence carries nine RND-type efflux pump genes that fall into the drug resistance type based on sequence homology. Homologues of two known *S. maltophilia* tripartite efflux pump operons are present, *smeABC* (Smlt4474-6) and *smeDEF* (Smlt4070-2), representing MFP, RND and OMP genes, respectively, in each case. *SmeABC* was first characterized in the clinical *S. maltophilia* isolate ULA511



**Figure 1**

Circular diagram of the main features of K279a. The circles show (outermost to innermost): 1, DNA coordinates (black); 2, color coded annotation (the CDSs are color coded according to function: blue = pathogenicity/adaptation; dark grey = essential metabolism; red = DNA replication/transcription/restriction-modification; green = transmembrane/outer membrane; cyan and magenta = degradation of large and small molecules, respectively; yellow = intermediary metabolism; light green = hypothetical; light blue = regulators; orange = conserved hypothetical; brown = pseudogenes; pink = transposons and phage); 3, laterally transferred regions (determined by Alien Hunter with a cut-off score of 15); 4, transposons and phage (pink); 5, pili and fimbriae (blue); 6, RND efflux transporters (green); 7, GC skew; 8, GC deviation.

[20], which is phylogenetically closely related to K279a [21]. Disruption of *smeAB* in ULA-511, or in a hyper-resistant mutant background, had no effect on drug resistance. However, disruption of *smeC* reduced the minimum inhibitory concentration (MIC) of a variety of antimicrobials against ULA-511, so *SmeC* may act as an OMP in at least one functional tripartite antimicrobial efflux pump [20].

*SmeDEF* is over-produced in a hyper-resistant mutant of the clinical isolate *S. maltophilia* D457 [22], which is phylogenetically quite distinct to K279a [21]. *SmeDEF* over-expression causes hyper-resistance to fluoroquinolones, chloramphenicol and tetracycline in K279a [17]. Hyper-expression occurs either through loss-of function mutations in the locally encoded TetR-type transcriptional repressor, *smeT* [17,23],

**Table 1**

**Characteristics of Sme efflux transporters in *S. maltophilia* K279a**

Systematic ID	Name	Known or putative regulation mechanism	Closest match to a known antimicrobial efflux protein
Smlt4474-4476	SmeABC	Two component regulator (SmeSR, Smlt4477-8)	<i>S. maltophilia</i> SmeABC [20]
Smlt4070-4072	SmeDEF	Tet-R type (SmeT, Smlt4073)	<i>S. maltophilia</i> SmeDEF [17,22]
Smlt1829-1833	SmeVWX	LysR type (Smlt1827)	51%, 56% and 48% amino acid identity, respectively, to <i>P. aeruginosa</i> MexEF-OprN [64]
Smlt2201-2202	SmeYZ	Two component regulator (Smlt2199-30)	44% and 59% amino acid identity, respectively, to AdeAB of <i>A. baumannii</i> [65]
Smlt3170-3171	SmeGH	TetR type (Smlt3169)	39% and 49% amino acid identity, respectively, to AcrAB of <i>M. morgani</i> [66]
Smlt3788-3787	SmeMN	?	<30% identity to other known antimicrobial efflux proteins
Smlt3925-3924	SmeOP	TetR type (Smlt3926)	<30% identity to other known antimicrobial efflux proteins
Smlt4279/4281	SmeIJK	?	41%, 50% and 44% amino acid identity, respectively, to MtdABC of <i>E. coli</i> [25]

or through undefined mutations, which may affect another regulator of the concentration of the activator [17,24]. Characteristics of the nine *S. maltophilia* RND efflux pumps are described in more detail in Table 1.

To determine involvement of the seven novel RND efflux pumps in intrinsic antimicrobial drug resistance in K279a, their genes were disrupted by suicide gene replacement to cause a significant intragenic deletion and frameshift mutation. MICs of a variety of antimicrobials were determined against the mutants in comparison to wild-type K279a. From this experiment, we conclude that SmeZ, SmeJ and SmeK are involved in intrinsic antimicrobial drug resistance in K279a (Table 2). A *smeJK* double mutant behaved identically to the individual mutants, leading to the conclusion that, as with their homologues *mtDBC* in *Escherichia coli* [25], their products cannot work separately. Disruption of *smeZ* markedly affects only aminoglycoside MICs; disruption of *smeJ* and/or *smeK* has a more general but subtle effect on resistance, lowering MICs of some aminoglycosides, fluoroquinolones and tetracyclines, but none dramatically.

Other known and putative antibiotic resistance genes in the genome specify resistance via a number of mechanisms to  $\beta$ -lactams, chloramphenicol, aminoglycosides, fluoroquinolones and macrolides (Table 3). Many of the resistance genes are located on small islands with no obvious mobile DNA features (determined by Alien Hunter [26]), and may not all be expressed. Experimentally determined antibiotic modifying enzymes produced by K279a are  $\beta$ -lactamases L1 and L2 specifying resistance to all clinically available  $\beta$ -lactams except the monobactams [27], and the aminoglycoside modifying enzymes APH 3'II and AAC 6'I that together confer resistance to all clinically available aminoglycosides except gentamicin [18]. It has been reported previously that the *S. maltophilia* L1 and L2  $\beta$ -lactamases might be encoded on a large 'plasmid-like element', but this was not confirmed using pulse-field gel electrophoresis [27]. Given that there is no plasmid in *S. maltophilia* isolate K279a, and that L1 and L2 are not encoded on a region of the chromosome that resembles an integrated plasmid, it is likely that the result reported previously reflected chromosomal contamination of a plasmid preparation, giving a false PCR positive for the L1 and L2 genes.

**Table 2**

**MICs of a variety of antimicrobials against *S. maltophilia* K279a and derivatives lacking specific functional RND efflux pump genes**

	Gent	Kan	Ami	Tob	Ery	Chor	Mero	Imi	Azt	Ctz	Pip	Tet	Min	Trim	Sul	Cipro	Levo	Nor
K279a	16	256	64	32	>1,024	6	32	256	256	8	64	16	0.25	32	64	2	4	32
<i>smeJ</i>	<b>8</b>	256	<b>32</b>	32	>1,024	6	32	256	512	8	64	<b>8</b>	<b>0.125</b>	32	64	<b>1</b>	4	32
<i>smeK</i>	<b>8</b>	256	<b>32</b>	32	>1,024	6	32	256	512	8	64	<b>8</b>	<b>0.125</b>	32	64	<b>1</b>	4	32
<i>smeJK</i>	<b>8</b>	256	<b>32</b>	32	>1,024	6	32	256	512	8	64	<b>8</b>	<b>0.125</b>	32	64	<b>1</b>	4	32
<i>smeZ</i>	<b>1</b>	<b>128</b>	<b>32</b>	<b>16</b>	>1,024	6	32	256	512	8	64	16	0.25	32	64	2	4	32

Gent, gentamicin; Kan, kanamycin; Ami, amikacin; Tob, tobramycin; Ery, erythromycin; Chor, chloramphenicol; Mero, meropenem; Imi, imipenem; Azt, aztreonam; Ctz, ceftazidime; Pip, piperacillin; Tet, tetracycline; Min, minocycline; Trim, trimpethoprim; Sul, sulphamethoxazole; Cipro, ciprofloxacin; Levo, levofloxacin; Nor, norfloxacin.

Entries in bold indicate changes of the MIC in the mutants compared to wild type K279a. The units used are in mg/L

**Table 3****Putative and known antimicrobial drug and heavy metal resistance genes in the *S. maltophilia* K279a genome sequence**

Substrate	Gene	Putative gene product
Aminoglycoside	Smlt0191	Putative aminoglycoside phosphotransferase
Aminoglycoside	Smlt1669	Putative aminoglycoside 2' N-acetyltransferase
Aminoglycoside	Smlt2120	Known aminoglycoside 3' phosphotransferase
Streptomycin	Smlt2336	Putative streptomycin 3" phosphotransferase/kinase
Aminoglycoside	Smlt3615	Known aminoglycoside 6'N acetyltransferase
Spectinomycin	Smlt2125/spcN	Putative spectinomycin phosphotransferase
Chloramphenicol	Smlt0620/cat	Putative chloramphenicol acetyltransferase
Fluoroquinolone	Smlt1071/qnrB	Putative quinolone resistance protein
Macrolides	Smlt0032	Putative MFS-type tripartite efflux transporter
Macrolides	Smlt1537-9	Putative ABC-type tripartite efflux transporter
Macrolides	Smlt2642-3	Putative ABC efflux transporter and MFP
Multidrug	Smlt1528-30/emrA,emrB	Putative MFS-type tripartite efflux transporter
Multidrug	Smlt1830-31;33/smeVWX	Putative RND-type tripartite efflux transporter
Multidrug	Smlt2201-2/smeYZ	Putative RND-type efflux protein and MFP
Multidrug	Smlt2796-8	Multidrug/fusaric acid resistance protein
Multidrug	Smlt3170-1/smeGH	Putative RND-type efflux protein and MFP
Multidrug	Smlt3787-78/smeMN	Putative RND-type efflux protein and MFP
Multidrug	Smlt3924-25/smeOP	Putative RND-type efflux protein and MFP
Multidrug	Smlt4072-74/smeDEF	Known RND-type tripartite efflux protein
Multidrug	Smlt4279-81/smeJKL	Putative RND-type tripartite efflux proteins and MFP
Multidrug	Smlt4474-76/smeABC	Known RND-type tripartite efflux protein
Beta-lactams	<i>bla</i> <sub>L1</sub>	Known Beta-lactamase - L1
Beta-lactams	<i>bla</i> <sub>L2</sub>	Known Beta-lactamase - L2
Kasugamycin	<i>ksgA</i>	Putative kasugamycin resistance protein
Organic solvents	<i>ostA</i>	Organic solvent tolerance protein
Peroxide	<i>ohrA</i>	Organic hydroperoxide
Mercury	<i>merRTPA</i>	Mercury resistance
Copper	<i>copLABMGCDF Smlt2445/Smlt2443 copL2A2B2 copCD</i>	Copper resistance
Arsenic	<i>arsRCHR2C2B Smlt2420</i>	Arsenic resistance

Genes encoding six other putative RND family tripartite efflux pumps are found in the K279a genome sequence. However, these are more closely related to cation/metal efflux pumps than to antimicrobial RND efflux pumps, and are designated *SmmABC* to *TUV*. K279a additionally encodes several alternative heavy metal resistance mechanisms that are associated with a complex mobile region of DNA. These include arsenic, mercury, and copper resistance. Alternative copper resistance genes are specified elsewhere in the genome. Heavy metal resistance (to cadmium via an efflux protein) has been described in *S. maltophilia* D457R [28].

DNA acquired by lateral gene transfer was identified using Alien Hunter [26]. Putative transposons, both conjugative and complex as well as insertion sequence (IS) elements were found in K279a. Throughout the genome there are seven

intact copies of a single unique IS element related to IS*Xac3* of *Xanthomonas campestris* pv *campestris* (*X. campestris*) 8004, and two pseudogenic copies. Additional IS elements present in the sequence include IS*Hne3*/IS*111A*-like and IS*Psy9*-like (Table 4). Intriguingly, a single putative streptomycin 3" phosphotransferase gene (Smlt2336) has inserted between genes *clpS* and *clpA* relative to the *X. campestris* genome. To one side of Smlt2336 is a set of 36 and 18 bp direct repeats, perhaps suggestive of a footprint of a mobile element that may have inserted then excised.

There is no evidence in K279a for a class one integron specifying sulfonamide resistance as has recently been seen in a number of *S. maltophilia* isolates [29], and K279a is sensitive to trimethoprim-sulphamethoxazole.

**Table 4****Potential mobile regions and their major characteristics**

Mobile region	Putative length, approx. (bp)	G+C content (%)	Putatively bounded by (repeat length, bp)	Major characteristics
Potential conjugative transposon	43,769	62.7	19	Hypotheticals, lipoproteins and an efflux protein cargo
Potential complex transposon insertion	97,538	61.9	18	Efflux transporters, mercury, arsenic and copper resistance, co-integrate resolution and integrases. May be a multiple insertion*
Potential complex transposon insertion	52,344	60.5	20	<i>Tra</i> genes and adhesins, DNA repair, conserved and unique hypotheticals. May be a multiple insertion. Carries IS elements and Tn5044 similarity
ISXac3-like	1,157	65.1	ND	Seven intact copies and two pseudogenic copies
ISHne3/IS11A-like	915	61.7	ND	Eleven intact copies
ISpsy9	1,352	58.8	ND	Four intact copies
Phage cluster 1	118,000	63.7	ND	Putative pseudogenic phage. Putative IS insertion and tRNA located centrally
Phage cluster 2	37,992	63.2	ND	Putative intact phage

Mobile regions were determined using an approach that combined using the Alien Hunter program, repeat analysis and by-eye comparisons between K279a and the *X. campestris* genome sequence by ACT analysis. \*CDS (Smlt2465) in this feature shares 72.5% identity with a previously characterized transposase, Tn5044, from a *Xanthomonas* spp. isolated from a heavy metal mine in Russia [67]. *Stenotrophomonas* was at that time classified as *Xanthomonas*. ND, not detected.

*S. maltophilia* harbor giant phage [30]; although potential prophages were identified in K279a, there is no evidence for giant lysogenic phage.

**Secretion systems and extracellular enzymes**

Type I, II (*sec*), IV and V (autotransporter) as well as the twin arginine secretion systems genes are present in the K279a genome sequence. Surprisingly, there are no type III secretion genes in K279a. Type III secretion components are related to the flagella apparatus [31]. The flagella apparatus of *S. maltophilia* is highly conserved with the *X. campestris* system and there is no evidence to suggest that these components could function in type III secretion. Secreted extracellular enzyme genes were found in the genome. K279a encodes non-hemolytic phospholipase C (plcN1, Smlt1755) as well as enzymes from the phospholipase D family. Phospholipase cleaves phospholipids to fatty acids and is implicated in virulence due to its ability to degrade cell membranes. There is evidence that phospholipases contribute towards virulence in *Burkholderia pseudomallei* [32]. Other extracellular enzymes, including DNase, gelatinase, hemolysin, lipases, proteinase K and proteases, have been characterized and implicated in disease in *S. maltophilia* [33]. The major extracellular protease of K279a, StmPr1 (Smlt0861), has also been implicated as a virulence determinant [34].

**Pili, fimbriae and adhesins**

*S. maltophilia* produces various pili/fimbriae that are implicated in adhesion and biofilm formation [35]. This type of aggregative behavior is likely to be associated with colonization of biotic and abiotic surfaces, evasion of the host immune response as well as increased drug resistance.

The Smf-1 fimbrial operon includes Smlt0706-Smlt0709. These 17 kDa subunit fimbriae mediate adherence, participate at early stages of biofilm formation [36] and can agglutinate red blood cells. Smf-1, seen as peritrichous semiflexible fimbriae of 5-7 nm under electron microscopy, are produced at 37°C but not 18°C. Two distinct loci, Smlt1508-12 and Smlt0732-6, comprise further sets of putative pili/fimbrial genes that include fimbrial subunit and chaperone/usher proteins.

A TadE-like pili/fimbrial gene cluster is located at Smlt2867-Smlt2875. In *Actinobacillus*, bundled Flp pili are required for tight adherence and strongly attached biofilm on solid surfaces *in vitro*, which is likely to be required in oral cavity colonization and initiation of periodontal disease [37].

Type IV pili are implicated in adherence and autoaggregation in enteropathogenic *E. coli*. In some species they have been associated with twitching motility and biofilm formation (for example, the obligate plant pathogen *Xylella fastidiosa* and *P. aeruginosa*). Subunits and associated apparatus specifying

the type IV pilus are scattered throughout the genome of K279a. K279a also carries a gene cluster that shares significant similarity with a locus specifying the giant cable pilus of *Burkholderia cenocepacia*. This pilus has been implicated in the pathogenicity of *B. cenocepacia* in CF patients [38]. However, not all pathogenic CF isolates of *B. cenocepacia* carry *cbl* genes; this can also be the case in other *Burkholderia* spp. [39]. Alternative potential adhesins are encoded in the genome, including an afimbrial adhesin and Hep-hag family adhesins.

In this bacteremia-associated isolate, K279a, there are three members of the YadA family of BuHA proteins that contain numerous Hep-Hag repeat domains [40]. Two hemagglutinin/hemolysin family proteins are present as pseudogenes. Hemolysin activator Smlt1389, and outer membrane surface filamentous hemagglutinin (FHA) Smlt1390 and Smlt4452 are present. Filamentous hemagglutinin is an important virulence factor in *Bordetella pertussis*, being involved in related adhesion and spread of bacteria through the respiratory tract [41].

### Intercellular and intracellular signaling

Quorum sensing (cell-cell signaling) is important in infection models of *P. aeruginosa*, and quorum-sensing signals that coordinate biofilm formation have been identified in CF sputum along with biofilm-like structures [42]. *S. maltophilia* also carries out cell-cell signaling; however, the *S. maltophilia* system does not employ the usual LuxIR regulators [43,44]. Instead, *S. maltophilia* uses the *Xanthomonas* and *Xylella* signaling system mediated by a diffusible signal molecule, DSF [45,46]. DSF activity has been detected in a number of strains of *S. maltophilia*, including K279a, and controls resistance to several antibiotics, aggregative and biofilm behavior and virulence in a nematode model [47]. The K279a proteome contains no *n*-acyl homoserine lactone (*N*-AHL) synthases of either the LuxI or LuxM type and no LuxS protein (implicated in autoinducer 2 synthesis in a wide range of bacteria). K279a does encode a single LuxR type regulator with an *N*-AHL autoinducer-binding domain. Such orphan LuxR-like proteins have been described in *Xanthomonas oryzae* pv *oryzae* (*X. oryzae*) [48] and *X. campestris* [49], which do not synthesize *N*-AHLs. These proteins may interact with a plant host component rather than bind *N*-AHLs.

DSF perception in *X. campestris* is linked to altered levels of the second messenger cyclic di-GMP through the action of the HD-GYP phosphodiesterase domain regulator RpfG [50]. Cyclic-di-GMP regulates a range of functions, including developmental transitions, adhesion, biofilm formation and virulence in diverse bacteria [51]. Cyclic-di-GMP levels are influenced by synthesis and degradation acted on by the protein domains GGDEF, EAL and HD-GYP. K279a encodes 33 proteins with a potential role in cyclic di-GMP turnover: 3 proteins with an EAL domain; 18 with a single GGDEF domain; 10 with GGDEF and EAL domains; and two HD-GYP

domain proteins, including RpfG. Most of these proteins contain additional signal input domains, suggesting that their activities (and therefore cyclic di-GMP levels) are responsive to diverse environmental cues.

### Polysaccharides


Polysaccharides are integral components of the extracellular matrix of bacterial biofilms and may play a role in resistance of bacteria to antibiotics. In xanthomonads, the *gum* gene cluster specifies production of the exopolysaccharide xanthan that is important in biofilm formation as well as being a commercially important product. *X. fastidiosa* produces fastidial gum, a truncated xanthan that is encoded by a reduced *gum* gene cluster [52]. There are no *gum* gene cluster orthologues in K279a; hence, this strain does not produce either xanthan or a modified version. Additionally, K279a does not carry genes for cellulose production, nor the exopolysaccharide cepacian, produced by some strains of *B. cenocepacia*.

Gene products implicated in the formation of intermediates of lipopolysaccharides and exopolysaccharides have been identified in K279a. XanAB are involved in UDP-glucose and GDP-mannose biosynthesis whilst RmlAC are involved in the synthesis and interconversion of TDP-sugars. XanB shares significant homology with phosphomannose isomerase, a key enzyme in the biosynthesis of *P. aeruginosa* alginate. Alginate is a key polysaccharide and is upregulated in CF sputum isolates from patients that have been infected with *P. aeruginosa* over a considerable length of time. Mutations in *xanB* and *rmlAC* affect biofilm formation and twitching motility in *S. maltophilia* WR-C [53]. The *xanA* gene, also known as *spgM*, is a phosphoglucomutase that shares similarity with *P. aeruginosa* *algC* [54]. K279a also specifies an orthologue of alginate lyase (Smlt1473), which is intriguing, since in CF lungs, the organisms are likely to be in contact with alginate-producing *P. aeruginosa*.

### Comparing the genomes of *S. maltophilia* and *X. campestris* - two sides of the same coin?

The K279a genome sequence was compared to that of *X. campestris* and *X. oryzae* using the Artemis Comparison Tool (ACT) (Figure 2). The extent of conserved regions between K279a and 8004 are difficult to visualize by ACT, mainly due to multiple chromosomal rearrangements. The first side of the 'coin' is illustrated by the use of K279a as a reference genome with a comparison of orthologous genes shared between K279a and sequenced xanthomonads on a circular genome representation. This comparison allows islands unique to K279a to be more clearly seen, the most obvious being the acquisition of a phage sited at 1,922,800 bp (Figure 3). Predicted functions of coding sequence (CDS) unique to K279a and those shared between 8004 and K279a are shown in Additional data file 1. Genes present in K279a that were not found in *X. campestris* may be applicable to human disease and are briefly described below.






**Figure 2**  
 Artemis Comparison Tool (ACT) plot of K279a versus *X. campestris* and *X. oryzae*. The ACT plot against *X. campestris* 8004 is shown at the top (NC\_007086), *S. maltophilia* K279a is in the centre, and *X. oryzae* KACC10331 is at the bottom (NC\_006834). Red bars denote matching regions, and blue bars denote inverted matching regions. The large number of genomic rearrangements can be seen.

The major regions of difference are phage and mobile elements; these encode both hypothetical and conserved hypotheticals as well as phage structural components (Table 3). In

addition, several efflux transporter proteins in K279a are not present in 8004. Fimbrial/pili gene clusters are either divergent or not present in 8004. Other K279a acquisitions include





**Figure 3**  
 Circular diagram showing xanthomonad orthologues. Circles show (outermost to innermost): 1, DNA coordinates of the reference genome K279a; 2, color coded annotation file, all reading frames in the same circle; 3-7, orthologous genes determined by reciprocal best match analysis (3, *X. campestris* pv *campestris* 8004 (NC\_007086); 4, *X. campestris* pv *campestris* 3391 (AE008922); 5, *X. campestris* *vesicatoria* (NC\_007508); 6, *X. axonopodis* *citri* (NC\_003919); 7, *X. oryzae* pv *oryzae* KACC10331 (NC\_006834)); 8, GC skew; 9, GC deviation.

hemagglutinins and hemolysins, two proteins with F5/8 type C coagulase domains, along with pseudogenes with hemagglutinin domains and similarities. Myosin cross-reactive antigen has also been acquired relative to *X. campestris*. Heavy metal resistance on a complex mobile element was acquired compared to 8004, as were some antibiotic resistance genes, especially those for aminoglycoside resistance. Although *S. maltophilia* is an obligate aerobe, the membrane-bound

nitrate reductase that supports growth in the absence of oxygen with nitrate as a terminal electron acceptor is present in some strains [55]. The potential for microoxic growth is suggested in K279a, with the putative acquisition of formate dehydrogenase (*fdn*), the selenocysteine tRNA synthesis genes required for the Sel codon in *fdnG*, and the membrane-bound nitrate reductase (*nar*). *Nar* employs a molybdenum cofactor, and K279a *nar* genes cluster with Mo cofactor bio-

synthesis and transport genes, and a member of the FNR/CRP family of transcriptional regulators (*fnr2*, Smlt2767). An FNR homologue present in the K279a gene cluster suggests that the associated genes are only produced under limiting oxygenation since *E. coli* FNR regulates the aerobic-anaerobic switch [56]. Microarray analysis of *P. aeruginosa* under conditions encountered in CF lung (modeled by growth in CF lung sputum) indicates that *nar* gene expression is elevated [57]. Another FNR family member (Smlt2159) is located elsewhere. The potential for growth under microoxic conditions may enhance the pathogenicity of this organism, for example, by increasing its ability to grow in biofilm. K279a has gained some heat shock proteins that may be needed during pathogenic growth. Both genera share a high number of TonB dependent receptor proteins, a peculiarity of xanthomonads and epsilon proteobacteria [58]. Using *X. campestris* 8004 as the reference genome in comparison to K279a, there are no large islands of acquisitions or losses. The flip side of the 'coin' is that genes present in *X. campestris* and absent in *S. maltophilia* are of relevance in plant disease (Figure 4). We can see the lack of the type III secretion system and *gum* gene cluster relative to *X. campestris*. Other plant pathogenic virulence determinants that are not present in K279a include the extracellular enzymes endoglucanase, polygalacturonate lyase, pectate lyase and cellulase. The *avr* genes involved in gene-for-gene resistance, such as *avrBS1* [59], are also not present in K279a. Further studies of the genomic comparisons between *X. campestris* and *S. maltophilia* may reveal additional genes of medical interest or of interest in plant pathogenesis.

## Conclusion

The genome sequence of the bacteremia-associated *S. maltophilia* isolate K279a carries a startling array of antimicrobial drug resistance gene determinants. Knockout mutagenesis confirms the involvement of a number of novel RND efflux genes in resistance to a variety of different classes of antimicrobials.

The current drug of choice for treating *S. maltophilia* infections is trimethoprim-sulphamethoxazole, but resistance is seen in *S. maltophilia* isolates due to a mobile determinant [29,60]. Other drugs with reasonable activity against *S. maltophilia* are minocycline and newer fluoroquinolones [60]. However, mutants resistant to these last resort drugs are readily selected *in vitro*. One mutation may be sufficient to cause resistance to these drugs, and worryingly, this mutation can be selected for in the presence of a front-line antimicrobial such as amikacin [17].

The panoply of antimicrobial drug resistance genes and mobile genetic elements is an issue of clinical concern. *S. maltophilia* can also provide antibiotic resistance protection for sensitive *P. aeruginosa* and *Serratia marcescens* strains growing nearby [61]. Even more importantly, the organism

potentially acts as a reservoir of antibiotic resistance determinants in medically relevant environments.

K279a possesses an unusual cell density-signaling pathway like that of its plant pathogenic xanthomonad relatives. K279a does produce extracellular enzymes such as protease StmPr1 and phospholipases; however, previous studies on clinical isolates have reported the production of other extracellular enzymes by *S. maltophilia*, suggesting that such virulence factors may be strain-specific. Comparison of K279a with *X. campestris* illustrates the movements of mobile genetic elements, the acquisition of potentially human pathogenic factors such as hemagglutinin, hemolysins and the loss of plant pathogenic factors such as the extracellular enzyme polygalacturonate lyase.


In conclusion, the *S. maltophilia* genome sequence reveals the capacity of this organism for environmental adaptations that presumably contribute to its persistence *in vivo*. As expected of a true opportunistic pathogen, the *S. maltophilia* genome does not suggest a highly virulent organism. However, the large number of pili/fimbrial genes does indicate a strong ability to attach to catheters and ventilators, from which infections of the blood or lungs arise. With its MDR phenotype and ability to attach, it is clear why this organism is persistent and difficult to eradicate. We are starting to build up a picture of an organism that is a true opportunist, which, while lacking many conventional key virulence determinants, has nevertheless emerged as a considerable threat.

## Materials and methods

### Sequencing strategy and annotation

*S. maltophilia* K279a was grown on Nutrient broth (Oxoid Cambridge, Cambridgeshire, UK) and genomic DNA was isolated using cetyltrimethylammonium bromide.

DNA was sonicated, size selected, and libraries were constructed in pUC19, pMAQ1b and pBACE3.6. The genome assembly was based on 3,381, 41,541 and 21,977 paired end-reads, respectively, from pUC19 libraries (of insert sizes 1.4-2.0 kb, 2.0-2.8 kb and 3.0-3.3 kb) and from 6,890, 314 and 69 paired end-reads, respectively, from pMAQ1b libraries (of insert sizes 5.5-6.0 kb, 9-10 kb and 10-12 kb), to give a 10.76-fold sequence coverage of the genome. We generated 1,250 and 106 reads, respectively, to produce a scaffold from 15-18 and 20-25 kb libraries in pBACE3.6. The genome was sequenced, finished and annotated as previously described [62]. To ensure that all bases were covered by reads on both strands or with different sequencing chemistries, and to fill gaps, 789 extra reads were generated. Repeats were bridged using read-pairs or end-sequenced PCR products. The total shotgun size was 53,580,262 Mb with a total genome coverage of 11.05-fold. Orthologous genes were determined by reciprocal best match analysis.



**Figure 4**  
 Circular diagram of orthologues shared between K279a and 8004. Circles show (outermost to innermost): 1, DNA coordinates of the reference genome 8004; 2, total CDS in both forward and reverse frames of the reference genome, *X. campestris* 8004 (blue); 3, shared genes between 8004 and K279a (red); 4, genes unique to 8004 (green); 5, GC skew; 6, GC deviation. The *gum* gene cluster and type III secretion (*hrp/hrc*) cluster from *X. campestris* 8004 can be seen clearly represented in the green (unique) circle at 2899664-2917444 and at 1424335-1427100, respectively.

**Disruption of putative efflux pump genes and MIC determination**

Genes were disrupted using a modified method of that previously described [17]. Genes were amplified by PCR in two non-overlapping fragments, with *Hind*III being introduced such that the two fragments could be ligated together, resulting in a mutant gene having a large deletion and a frameshift mutation. The primers used are listed in Additional data file 2. Mutated genes were used to replace wild-type sequences on

the chromosome of K279a using the gene replacement approach described previously. Agar dilution MICs of antimicrobials against K279a and its derivatives were determined according to British Society for Antimicrobial Chemotherapy (BSAC)-approved methods [63].

## Abbreviations

ACT, Artemis Comparison Tool; BSAC, British Society for Antimicrobial Chemotherapy; CDS, coding sequence; CF, cystic fibrosis; IS, insertion sequence; MDR, multi-drug resistant; MFP, membrane fusion protein; MIC, minimum inhibitory concentration; *N*-AHL, *n*-acyl homoserine lactone; OMP, outer membrane protein; RND, resistance-nodulation-division.

## Authors' contributions

LCC, MBA, JMD and JP wrote the paper. GSV, AO, NP, AK, TC and EA provided DNA or analysis tools. VCG, DS, CA, and MAQ carried out experiments. LCC, VCG, JMD, GSV, MS, DS, AL, LM, KS, RS, SR, MAJ, DH, CC, SDB, JP, NRT and MBA analyzed data.

## Additional data files

The following additional data are available with the online version of this paper. Additional data file 1 shows the shared genes between K279a and *X. campestris*, and the genes unique to K279a determined by reciprocal best match analysis. Additional data file 2 is a table listing the primer sequences used in the generation of gene knock-outs.

## Acknowledgements

The authors thank the core informatics and sequencing departments at the Wellcome Trust Sanger Institute. This work was supported by the Wellcome Trust and the BSAC.

## References

- Fernandes P: **Antibacterial discovery and development - the failure of success?** *Nat Biotechnol* 2006, **24**:1497-1503.
- Paterson DL, Lipman J: **Returning to the pre-antibiotic era in the critically ill: the XDR problem.** *Crit Care Med* 2007, **35**:1789-1791.
- Martinez JL, Baquero F, Andersson DI: **Predicting antibiotic resistance.** *Nat Rev Microbiol* 2007, **5**:958-965.
- Torres JA, Villegas MV, Quinn JP: **Current concepts in antibiotic-resistant gram-negative bacteria.** *Expert Rev Anti Infect Ther* 2007, **5**:833-843.
- Falagas ME, Kopterides P: **Risk factors for the isolation of multi-drug-resistant *Acinetobacter baumannii* and *Pseudomonas aeruginosa*: a systematic review of the literature.** *J Hosp Infect* 2006, **64**:7-15.
- Mesaros N, Nordmann P, Plésiat P, Roussel-Delvallez M, Van Eldere J, Glupczynski Y, Van Laethem Y, Jacobs F, Lebecque P, Malfroot A, Tulkens PM, Van Bambeke F: ***Pseudomonas aeruginosa*: resistance and therapeutic options at the turn of the new millennium.** *Clin Microbiol Infect* 2007, **13**:560-578.
- Sader HS, Jones RN: **Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilli.** *Int J Antimicrob Agents* 2005, **25**:95-109.
- Lockhart SR, Abramson MA, Beekmann SE, Gallagher G, Riedel S, Diekema DJ, Quinn JP, Doern GV: **Antimicrobial resistance among Gram-negative bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004.** *J Clin Microbiol* 2007, **45**:3352-3359.
- Senol E: ***Stenotrophomonas maltophilia*: the significance and role as a nosocomial pathogen.** *J Hosp Infect* 2004, **57**:1-7.
- Ribbeck-Busch K, Roder A, Hasse D, de Boer W, Martinez JL, Hagemann M, Berg G: **A molecular biological protocol to distinguish potentially human pathogenic *Stenotrophomonas maltophilia* from plant-associated *Stenotrophomonas rhizophila*.** *Environ Microbiol* 2005, **7**:1853-1858.
- Minkwitz A, Berg G: **Comparison of antifungal activities and 16S ribosomal DNA sequences of clinical and environmental isolates of *Stenotrophomonas maltophilia*.** *J Clin Microbiol* 2001, **39**:139-145.
- Berg G, Roskot N, Smalla K: **Genotypic and phenotypic relationships between clinical and environmental isolates of *Stenotrophomonas maltophilia*.** *J Clin Microbiol* 1999, **37**:3594-3600.
- Gould VC, Okazaki A, Avison MB: **Beta-lactam resistance and beta-lactamase expression in clinical *Stenotrophomonas maltophilia* isolates having defined phylogenetic relationships.** *J Antimicrob Chemother* 2006, **57**:199-203.
- Goss CH, Mayer-Hamblett N, Aitken ML, Rubenfeld GD, Ramsey BW: **Association between *Stenotrophomonas maltophilia* and lung function in cystic fibrosis.** *Thorax* 2004, **59**:955-959.
- Hadjilias D, Steele MP, Chaparro C, Singer LG, Waddell TK, Hutchison MA, Davis RD, Tullis DE, Palmer SM, Keshavjee S: **Survival of lung transplant patients with cystic fibrosis harboring panresistant bacteria other than *Burkholderia cepacia*, compared with patients harboring sensitive bacteria.** *J Heart Lung Transplant* 2007, **26**:834-838.
- Avison MB, von Heldreich CJ, Higgins CS, Bennett PM, Walsh TR: **A TEM-2beta-lactamase encoded on an active Tn I-like transposon in the genome of a clinical isolate of *Stenotrophomonas maltophilia*.** *J Antimicrob Chemother* 2000, **46**:879-884.
- Gould VC, Avison MB: **SmeDEF-mediated antimicrobial drug resistance in *Stenotrophomonas maltophilia* clinical isolates having defined phylogenetic relationships.** *J Antimicrob Chemother* 2006, **57**:1070-1076.
- Okazaki A, Avison MB: **Aph(3')-IIc, an aminoglycoside resistance determinant from *Stenotrophomonas maltophilia*.** *Antimicrob Agents Chemother* 2007, **51**:359-360.
- Poole K: **Efflux pumps as antimicrobial resistance mechanisms.** *Ann Med* 2007, **39**:162-176.
- Li XZ, Zhang L, Poole K: **SmeC, an outer membrane multidrug efflux protein of *Stenotrophomonas maltophilia*.** *Antimicrob Agents Chemother* 2002, **46**:333-343.
- Gould VC, Okazaki A, Howe RA, Avison MB: **Analysis of sequence variation among smeDEF multi drug efflux pump genes and flanking DNA from defined 16S rRNA subgroups of clinical *Stenotrophomonas maltophilia* isolates.** *J Antimicrob Chemother* 2004, **54**:348-353.
- Alonso A, Martinez JL: **Cloning and characterization of SmeDEF, a novel multidrug efflux pump from *Stenotrophomonas maltophilia*.** *Antimicrob Agents Chemother* 2000, **44**:3079-3086.
- Sanchez P, Alonso A, Martinez JL: **Cloning and characterization of SmeT, a repressor of the *Stenotrophomonas maltophilia* multidrug efflux pump SmeDEF.** *Antimicrob Agents Chemother* 2002, **46**:3386-3393.
- Sanchez P, Alonso A, Martinez JL: **Regulatory regions of smeDEF in *Stenotrophomonas maltophilia* strains expressing different amounts of the multidrug efflux pump SmeDEF.** *Antimicrob Agents Chemother* 2004, **48**:2274-2276.
- Baranova N, Nikaido H: **The baeSR two-component regulatory system activates transcription of the yegMNOB (mdtABCD) transporter gene cluster in *Escherichia coli* and increases its resistance to novobiocin and deoxycholate.** *J Bacteriol* 2002, **184**:4168-4176.
- Vernikis GS, Parkhill J: **Interpolated variable order motifs for identification of horizontally acquired DNA: revisiting the *Salmonella* pathogenicity islands.** *Bioinformatics* 2006, **22**:2196-2203.
- Avison MB, Higgins CS, von Heldreich CJ, Bennett PM, Walsh TR: **Plasmid location and molecular heterogeneity of the L1 and L2 beta-lactamase genes of *Stenotrophomonas maltophilia*.** *Antimicrob Agents Chemother* 2001, **45**:413-419.
- Alonso A, Sanchez P, Martinez JL: ***Stenotrophomonas maltophilia* D457R contains a cluster of genes from gram-positive bacteria involved in antibiotic and heavy metal resistance.** *Antimicrob Agents Chemother* 2000, **44**:1778-1782.
- Toleman MA, Bennett PM, Bennett DM, Jones RN, Walsh TR: **Global emergence of trimethoprim/sulfamethoxazole resistance in *Stenotrophomonas maltophilia* mediated by acquisition of sul genes.** *Emerg Infect Dis* 2007, **13**:559-565.
- Chang HC, Chen CR, Lin JW, Shen GH, Chang KM, Tseng YH, Weng SF: **Isolation and characterization of novel giant *Stenotropho-***



- monas maltophilia phage phiSMA5.** *Appl Environ Microbiol* 2005, **71**:1387-1393.
31. Wilhelm G, Lehmann V, Krauss K, Lehnert B, Richter S, Ruckdeschel K, Heesemann J, Trulzsch K: **Yersinia enterocolitica type III secretion depends on the proton motive force but not on the flagellar motor components MotA and MotB.** *Infect Immun* 2004, **72**:4004-4009.
  32. Korbsrisate S, Tomaras AP, Damnin S, Ckumdee J, Srinon V, Lengwehasatit I, Vasil ML, Suparak S: **Characterization of two distinct phospholipase C enzymes from Burkholderia pseudomallei.** *Microbiology* 2007, **153**:1907-1915.
  33. Travassos LH, Pinheiro MN, Coelho FS, Sampaio JL, Merquior VL, Marques EA: **Phenotypic properties, drug susceptibility and genetic relatedness of Stenotrophomonas maltophilia clinical strains from seven hospitals in Rio de Janeiro, Brazil.** *J Appl Microbiol* 2004, **96**:1143-1150.
  34. Windhorst S, Frank E, Georgieva DN, Genov N, Buck F, Borowski P, Weber W: **The major extracellular protease of the nosocomial pathogen Stenotrophomonas maltophilia: characterization of the protein and molecular cloning of the gene.** *J Biol Chem* 2002, **277**:11042-11049.
  35. de Oliveira-Garcia D, Dall'Agnol M, Rosales M, Azzuz AC, Martinez MB, Giron JA: **Characterization of flagella produced by clinical strains of Stenotrophomonas maltophilia.** *Emerg Infect Dis* 2002, **8**:918-923.
  36. de Oliveira-Garcia D, Dall'Agnol M, Rosales M, Azzuz AC, Alcantara N, Martinez MB, Giron JA: **Fimbriae and adherence of Stenotrophomonas maltophilia to epithelial cells and to abiotic surfaces.** *Cell Microbiol* 2003, **5**:625-636.
  37. Tomich M, Planet PJ, Figurski DH: **The tad locus: postcards from the widespread colonization island.** *Nat Rev Microbiol* 2007, **5**:363-375.
  38. Urban TA, Goldberg JB, Forstner JF, Sajjan US: **Cable pili and the 22-kilodalton adhesin are required for Burkholderia cenocepacia binding to and transmigration across the squamous epithelium.** *Infect Immun* 2005, **73**:5426-5437.
  39. Carvalho AP, Ventura GM, Pereira CB, Leão RS, Folescu TW, Higa L, Teixeira LM, Plotkowski MC, Merquior VL, Albano RM, Marques EA: **Burkholderia cenocepacia, B. multivorans, B. ambifaria and B. vietnamiensis isolates from cystic fibrosis patients have different profiles of exoenzyme production.** *APMIS* 2007, **115**:311-318.
  40. Tiyawitsutsri R, Holden MT, Tumapa S, Rengpipat S, Clarke SR, Foster SJ, Nierman WC, Day NP, Peacock SJ: **Burkholderia Hep\_Hag autotransporter (BuHA) proteins elicit a strong antibody response during experimental glanders but not human melioidosis.** *BMC Microbiol* 2007, **7**:19.
  41. Colombi D, Oliveira ML, Campos IB, Monedero V, Perez-Martinez G, Ho PL: **Haemagglutination induced by Bordetella pertussis filamentous haemagglutinin adhesin (FHA) is inhibited by antibodies produced against FHA(430-873) fragment expressed in Lactobacillus casei.** *Curr Microbiol* 2006, **53**:462-466.
  42. Pearson JP, Feldman M, Iglewski BH, Prince A: **Pseudomonas aeruginosa cell-to-cell signaling is required for virulence in a model of acute pulmonary infection.** *Infect Immun* 2000, **68**:4331-4334.
  43. Eberl L: **Quorum sensing in the genus Burkholderia.** *Int J Med Microbiol* 2006, **296**:103-110.
  44. Bjarnsholt T, Givskov M: **The role of quorum sensing in the pathogenicity of the cunning aggressor Pseudomonas aeruginosa.** *Anal Bioanal Chem* 2007, **387**:409-414.
  45. Barber CE, Tang JL, Feng JX, Pan MQ, Wilson TJ, Slater H, Dow JM, Williams P, Daniels MJ: **A novel regulatory system required for pathogenicity of Xanthomonas campestris is mediated by a small diffusible signal molecule.** *Mol Microbiol* 1997, **24**:555-566.
  46. Scarpari LM, Lambais MR, Silva DS, Carraro DM, Carrer H: **Expression of putative pathogenicity-related genes in Xylella fastidiosa grown at low and high cell density conditions in vitro.** *FEMS Microbiol Lett* 2003, **222**:83-92.
  47. Fouhy Y, Scanlon K, Schouest K, Spillane C, Crossman L, Avison MB, Ryan RP, Dow JM: **Diffusible signal factor-dependent cell-cell signaling and virulence in the nosocomial pathogen Stenotrophomonas maltophilia.** *J Bacteriol* 2007, **189**:4964-4968.
  48. Ferluga S, Bigirimana J, Hofte M, Venturi V: **A luxR homologue of Xanthomonas oryzae pv oryzae is required for optimal rice virulence.** *Mol Plant Pathol* 2007, **8**:529-538.
  49. Zhang L, Jia Y, Wang L, Fang R: **A proline iminopeptidase gene upregulated in planta by a LuxR homologue is essential for pathogenicity of Xanthomonas campestris pv. campestris.** *Mol Microbiol* 2007, **65**:121-136.
  50. Ryan RP, Fouhy Y, Lucey JF, Crossman LC, Spiro S, He YW, Zhang LH, Heeb S, Cámara M, Williams P, Dow JM: **Cell-cell signaling in Xanthomonas campestris involves an HD-GYP domain protein that functions in cyclic di-GMP turnover.** *Proc Natl Acad Sci USA* 2006, **103**:6712-6717.
  51. Jenal U, Malone J: **Mechanisms of cyclic-di-GMP signaling in bacteria.** *Annu Rev Genet* 2006, **40**:385-407.
  52. da Silva FR, Vettore AL, Kemper EL, Leite A, Arruda P: **Fastidious gum: the Xylella fastidiosa exopolysaccharide possibly involved in bacterial pathogenicity.** *FEMS Microbiol Lett* 2001, **203**:165-171.
  53. Huang TP, Somers EB, Wong AC: **Differential biofilm formation and motility associated with lipopolysaccharide/exopolysaccharide-coupled biosynthetic genes in Stenotrophomonas maltophilia.** *J Bacteriol* 2006, **188**:3116-3120.
  54. McKay GA, Woods DE, MacDonald KL, Poole K: **Role of phosphoglucomutase of Stenotrophomonas maltophilia in lipopolysaccharide biosynthesis, virulence, and antibiotic resistance.** *Infect Immun* 2003, **71**:3068-3075.
  55. Woodard LM, Biellie AR, Eisses JF, Ketchum PA: **Occurrence of nitrate reductase and molybdopterin in Xanthomonas maltophilia.** *Appl Environ Microbiol* 1990, **56**:3766-3771.
  56. Spiro S, Guest JR: **Adaptive responses to oxygen limitation in Escherichia coli.** *Trends Biochem Sci* 1991, **16**:310-314.
  57. Palmer KL, Brown SA, Whiteley M: **Membrane-bound nitrate reductase is required for anaerobic growth in cystic fibrosis sputum.** *J Bacteriol* 2007, **189**:4449-4455.
  58. Koebnik R: **TonB-dependent trans-envelope signaling: the exception or the rule?** *Trends Microbiol* 2005, **13**:343-347.
  59. Ronald PC, Staskawicz BJ: **The avirulence gene avr BsI from Xanthomonas campestris pv. vesicatoria encodes a 50-kD protein.** *Mol Plant Microbe Interact* 1988, **1**:191-198.
  60. Nicodemo AC, Paez JI: **Antimicrobial therapy for Stenotrophomonas maltophilia infections.** *Eur J Clin Microbiol Infect Dis* 2007, **26**:229-237.
  61. Kataoka D, Fujiwara H, Kawakami T, Tanaka Y, Tanimoto A, Ikawa S, Tanaka Y: **The indirect pathogenicity of Stenotrophomonas maltophilia.** *Int J Antimicrob Agents* 2003, **22**:601-606.
  62. Young JP, Crossman LC, Johnston AV, Thomson NR, Ghazoui ZF, Hull KH, Wexler M, Curson AR, Todd JD, Poole PS, Mauchline TH, East AK, Quail MA, Churcher C, Arrowsmith C, Cherevach I, Chillingworth T, Clarke K, Cronin A, Davis P, Fraser A, Hance Z, Hauser H, Jagels K, Moule S, Mungall K, Norbertczak H, Rabinowitsch E, Sanders M, Simmonds M, et al.: **The genome of Rhizobium leguminosarum has recognizable core and accessory components.** *Genome Biol* 2006, **7**:R34.
  63. **BSAC: Susceptibility Testing** [[http://www.bsac.org.uk/susceptibility\\_testing.cfm](http://www.bsac.org.uk/susceptibility_testing.cfm)]
  64. Sobel ML, Neshat S, Poole K: **Mutations in PA2491 (mexS) promote MexT-dependent mexEF-oprN expression and multidrug resistance in a clinical strain of Pseudomonas aeruginosa.** *J Bacteriol* 2005, **187**:1246-1253.
  65. Magnet S, Courvalin P, Lambert T: **Resistance-nodulation-cell division-type efflux pump involved in aminoglycoside resistance in Acinetobacter baumannii strain BM4454.** *Antimicrob Agents Chemother* 2001, **45**:3375-3380.
  66. Ruzin A, Keeney D, Bradford PA: **AcrAB efflux pump plays a role in decreased susceptibility to tigecycline in Morganella morganii.** *Antimicrob Agents Chemother* 2005, **49**:791-793.
  67. Kholodii G, Yurieva O, Mindlin S, Gorlenko Z, Rybochkin V, Nikiforov V: **Tn a novel Tn3 family transposon coding for temperature-sensitive mercury resistance.** *Res Microbiol* 2004, **151**:291-302.